Neurochem Inc. (Neurochem), incorporated on June 17, 1993, is a biopharmaceutical company focused on the development and commercialization of therapeutics to address unmet medical needs. The Company's product candidates are Eprodisate (Fibrillex), Tramiprosate (Alzhemed) and Tramiprosate (Cerebril). Neurochem's investigational product candidates consist of small molecules that have been shown in vivo to reduce amyloid deposition. Eprodisate (Fibrillex) and tramiprosate (Alzhemed) and Cerebril, the Company's advanced product candidates, are based on this technology. Eprodisate (Fibrillex) is targeted to treat Amyloid A amyloidosis (AA amyloidosis). Tramiprosate (Alzhemed) is being developed for the treatment of Alzheimer's disease (AD). Tramiprosate (Cerebril) is targeted for the treatment of hemorrhagic stroke due to Cerebral Amyloid Angiopathy (CAA). Neurochem also has ongoing discovery programs that are focused on the development of next-generation AD compounds and a vaccine for the prevention and/or treatment of AD. Eprodisate (Fibrillex) for Amyloid A amyloidosis Eprodisate (Fibrillex) has received fast-track designation from the United States Food & Drug Administration (FDA). It has been selected by the cardio-renal drug product division of the FDA to be part of the continuous marketing applications Pilot I and Pilot II programs. Eprodisate (Fibrillex) has also received orphan drug designation status in the United States and orphan medicinal product designation in Europe. The Phase II/III clinical trial completed in December 2004, was a two-year, international, multi-center, randomized, double-blind, placebo-controlled and parallel-designed trial conducted to investigate the safety and efficacy of eprodisate (Fibrillex) in 183 patients suffering from AA amyloidosis at 27 centers around the world, including the United States, Europe, Turkey and Israel. More than 80% of patients who completed the Phase II/III clinical trial joined an open-label Phase II/III extension study and are receiving eprodisate (Fibrillex) for an additional three and a half years. In December 2004, through its wholly owned subsidiary, Neurochem (International) Limited, the Company entered into a definitive collaboration and distribution agreement with Centocor, Inc., a wholly owned subsidiary of Johnson & Johnson, Inc., for the distribution rights for eprodisate (Fibrillex) for the prevention and treatment of AA amyloidosis. Neurochem has submitted to the FDA the final modules of its new drug application (NDA) for eprodisate (Fibrillex) in February 2006. The Company is seeking marketing approval of eprodisate (Fibrillex(TM) for the treatment of AA amyloidosis. Tramiprosate (Alzhemed) for Alzheimer's Disease Tramiprosate (Alzhemed) is in two Phase III clinical trials, designed to assess the safety, efficacy and disease-modifying potential of tramiprosate (Alzhemed) in mild-to-moderate AD patients. In June 2004, Neurochem initiated a North American Phase III clinical trial for tramiprosate (Alzhemed). The trial is a large multi-center, international, randomized, double-blind, placebo-controlled and parallel group study that includes 1,052 patients with mild-to-moderate AD who are being treated for 18 months. The trial is being conducted at close to 70 clinical centers in Canada and the United States. The primary efficacy endpoints of this study include the evaluation of cognitive abilities and a global measure of performance utilizing the Alzheimer's Disease Assessment Scale-cognitive subpart (ADAS-cog) and the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB). Tramiprosate (Alzhemed) is the Company's first-generation product candidate for AD. In September 2005, Neurochem initiated a European Phase III clinical trial for tramiprosate (Alzhemed). As with the North American clinical trial, the European study is a large multi-center, international, randomized, double-blind, placebo-controlled and parallel group study. As of February 2006, 288 patients had been screened for eligibility and of these, 96 had been random

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for NRMX